Improving our understanding of immunotherapy in high-risk neuroblastoma
Understanding and improving the mechanism of action of anti-GD2 monoclonal antibody therapy in neuroblastoma
Understanding drug resistance in neuroblastoma to develop personalised treatments
Overcoming drug resistance for efficacious neuroblastoma therapeutics
Can we identify an 'ultra-high-risk' type of neuroblastoma?
A pilot study of expression profiling using RNAseq from formalin fixed neuroblastoma and paired diagnostic and relapsed frozen neuroblastomas.
Understanding the genetics of poor outcome neuroblastoma to improve treatment
A genome wide study of unresectable, MYCN non-amplied, unfavourable histology neuroblastomas in patients older than 18 months of age
Understanding why some children with neuroblastoma have worse survival or respond badly to treatment
Targeting the Fanconi Anaemia pathyway in neuroblastoma
Using genetics to find targets for new drugs to treat relapsed neuroblastoma
Characterisation and validation of recurrently mutated genes in relapsed neuroblastoma as targets for novel therapies
Understanding genetic changes in neuroblastoma cells to pave the way for targeted treatments
Investigation of the effects of DNA repair inhibitors in pre-clinical models of neuroblastomas with ATM, MYCN and TP53 abnormalities
Developing new treatments for high-risk neuroblastoma
Pre-clinical efficacy and biomarker studies of ALK, MAPK and MDM2-p53 inhibitor combinations in neuroblastoma
Improving our understanding of the genetics of neuroblastoma
Understanding neuroblastoma heterogeneity: genetic studies of circulating neuroblastoma tumour cells